DEXLANSOPRAZOLE (dexlansoprazole) by Pfizer is proton pump inhibitors [moa]. Approved for older for: healing of all grades of erosive esophagitis (ee), older for healing of all grades of erosive esophagitis (ee) for up to eight weeks, older to maintain healing of ee and 3 more indications. First approved in 2017.
Drug data last refreshed 19h ago
Proton Pump Inhibitors
Proton Pump Inhibitor
Worked on DEXLANSOPRAZOLE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian Federation
A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules